MRCT and Pharmidex form drug discovery collaboration


Pharmidex will provide all in vivo ADME/PK drug discovery support to MRCT in 2010

Medical Research Council Technology (MRCT), based in London, UK, has chosen Pharmidex as its supplier of pharmacokinetic and ADME studies.

The partnership will give MRCT access to high quality laboratory services and expertise that will enable it to develop efficient, high quality studies.

Pharmidex provides ADME/PK, drug safety and bioanalytical services for lead optimisation and drug development activities.

The company also has a CNS solutions platform including NeuroPK and NeuroPD for direct assessment of drug levels and biochemical responses in any brain region.